While biopharmaceutical giant Amgen (AMGN) managed to eke out a modest gain on Friday, the past week has been rough, with AMGN stock losing 4%. Adding insult to injury, the equity is rated as a 72% Strong Sell by the Barchart Technical Opinion indicator. Despite the volatility risks, contrarians could be justified in betting on the healthcare juggernaut.Just like in America’s favorite pastime, the use of sabermetrics doesn’t guarantee that you’ll win baseball games. However, a consistent, empirical framewor ...